Latest Asx Disclosures News

VHM Limited has clarified that a non-binding US$200 million letter of interest from the US Export-Import Bank for its Goschen project is not material to its share price, confirming full compliance with ASX disclosure rules despite recent market speculation.

Carawine Resources Limited’s shares have been suspended from trading following a Federal Court ruling that allows QGold Pty Ltd to compulsorily acquire all remaining shares it does not own.

Eclipse Metals has commenced mobilisation for its 2025 diamond drilling program at the Grønnedal Rare Earths Carbonatite Complex in Greenland, aiming to expand a significant rare earth mineral resource rich in critical magnet metals.

Nelson Resources has confirmed it is in confidential negotiations for a Right to Mine contract, explaining recent unusual trading activity in its shares. The company maintains compliance with ASX disclosure rules while awaiting contract finalisation.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

Control Bionics Limited has confirmed its compliance with ASX continuous disclosure rules following an inquiry about the timing and content of its financial results announcements.

Ramsay Health Care has clarified that its underlying earnings for FY25 aligned closely with market consensus, despite a significant non-cash impairment impacting statutory profits. The company confirms compliance with ASX disclosure rules amid share price volatility.

Rewardle Holdings clarifies its complex relationship with CloudHolter and updates on Pepper Leaf loan litigation, addressing ASX concerns over financial reporting delays.

RPMGlobal Holdings clarifies the reasons behind withdrawing its FY2025 earnings guidance following the divestment of its Advisory business, providing detailed updates on software segment performance and compliance with ASX disclosure rules.

Codan Limited has clarified that its FY25 financial results aligned closely with market forecasts despite a notable share price jump following its earnings release. The company detailed its compliance with ASX disclosure rules and attributed the price movement to broader macroeconomic factors.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

Pengana International Equities has acknowledged breaching ASX disclosure rules by sharing details of a new private credit strategy with media before official announcement, prompting a policy overhaul.